- Samsung Bioepis and Organon expanded their Canadian partnership, granting Organon exclusive commercialization rights to Pyzchiva (ustekinumab biosimilar), referencing Stelara.
- While Organon will handle commercialization in Canada, Samsung Bioepis will retain responsibility for development, manufacturing, and regulatory activities. Pyzchiva is expected to launch in 2026.
- The agreement broadens the companies’ Canadian biosimilar portfolio from five to six products, adding Pyzchiva alongside Hadlima, Brenzys, Renflexis, Aybintio, and Ontruzant.
- Pyzchiva is approved for multiple inflammatory conditions, including plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis, supporting broader patient access to lower-cost biologic treatment options in Canada.
Takeaways:
Expanded Canadian partnership positions Organon as the exclusive commercialization partner for Samsung Bioepis’s ustekinumab biosimilar Pyzchiva (Stelara reference), creating a six-product biosimilar portfolio in Canada and strengthening Organon’s inflammatory disease franchise.
Source: Businesswire
